The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity

British Journal of Cancer

Volumn 109, Issue 5, 2013, Pages 1206-1213

  Hemmerle, T ^a   Probst, P ^a   Giovannoni, L ^b   Green, A J ^c   Meyer, T ^c   Neri, D ^a  

^a ETH ZURICH   (Switzerland)

^b Philogen SpA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

vascular targeting; immunocytokines; sarcoma; tumour necrosis factor; doxorubicin; oncofetal fibronectin

Indexed keywords

ANTIBODY FRAGMENT F8 TUMOR NECROSIS FACTOR ALPHA; ANTIBODY FRAGMENT L19 TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; DOXORUBICIN; FIBRONECTIN; HYBRID PROTEIN; IODINE 131; ONCOFETAL ANTIGEN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CONTROLLED STUDY; CT SPECT SCANNER; DRUG DISTRIBUTION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RADIOIMMUNOTHERAPY; RECOMMENDED DRUG DOSE; SARCOMA; SARCOMA CELL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR IMMUNITY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; RECOMBINANT FUSION PROTEINS; SARCOMA; TUMOR NECROSIS FACTORS;

EID: 84883741949     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.421     Document Type: Article

References (46)

1. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349): 377-380. (Pubitemid 28063372)
2. Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L (2010) Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer 127(1): 101-110.
3. Balza E, Mortara L, Sassi F, Monteghirfo S, Carnemolla B, Castellani P, Neri D, Accolla RS, Zardi L, Borsi L (2006) Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 12(8): 2575-2582.
4. Bassani-Sternberg M, Barnea E, Beer I, Avivi I, Katz T, Admon A (2010) Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci USA 107(44): 18769-18776.
5. Berendt MJ, North RJ, Kirstein DP (1978) The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med 148(6): 1550-1559. (Pubitemid 9084030)
6. Bermudes D, Low KB, Pawelek J, Feng M, Belcourt M, Zheng LM, King I (2001) Tumour-selective Salmonella-based cancer therapy. Biotechnol Genet Eng Rev 18: 219-233. (Pubitemid 32778001)
7. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM (2005) Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11(19 Pt 2): 7053s-7063s. (Pubitemid 41428704)
8. Berndt A, Kollner R, Richter P, Franz M, Voigt A, Borsi L, Giavazzi R, Neri D, Kosmehl H (2010) A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol 133(4): 467-475.
9. Bertilaccio MT, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M, Jachetti E, Greenberg NM, Corti A, Bellone M (2008) Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate 68(10): 1105-1115. (Pubitemid 351875182)
10. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102(13): 4384-4392. (Pubitemid 37494099)
11. Borsi L, Castellani P, Allemanni G, Neri D, Zardi L (1998) Preparation of phage antibodies to the ED-A domain of human fibronectin. Exp Cell Res 240(2): 244-251. (Pubitemid 28371105)
12. Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353(7): 701-711. (Pubitemid 41175678)
13. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A (2002) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62(3): 867-874. (Pubitemid 34126966)
14. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B (2001) Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 98(26): 15155-15160. (Pubitemid 34013985)
15. Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D (2005) Engineered vascular-targeting antibodyinterferon-gamma fusion protein for cancer therapy. Int J Cancer 116(2): 304-313. (Pubitemid 40967270)
16. Eggermont AM, Schraffordt Koops H, Klausner JM, Schlag PM, Kroon BB, Ben-Ari G, Lejeune FJ (1997) Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res 91: 189-203.
17. Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, Bombardieri E, Grana C, Giovannoni L, Neri D, Menssen HD, Mariani G (2012) Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med 53(6): 922-927.
18. Ferrari S, Casali P, Blay J, Tonini G, Le Cesne A, ALi N, Perfetti V, Palmerini E, Plalassini E, Ray-Coquard I, Vincenzi B, Domont J, Marchesi E, Marrari A, Cassier P, Silletta M, Stacchiotti S, Lambiase A, Bordignon C (2013) Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS). J Clin Oncol 31: 10568.
19. Frey K, Fiechter M, Schwager K, Belloni B, Barysch MJ, Neri D, Dummer R (2011) Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol 20(8): 685-688.
20. Hoogenboom HR, Winter G (1992) By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 227(2): 381-388.
21. Kita H, He XS, Gershwin ME (2003) Application of tetramer technology in studies on autoimmune diseases. Autoimmun Rev 2(1): 43-49. (Pubitemid 37443871)
22. Kontermann RE (2012) Antibody-cytokine fusion proteins. Arch Biochem Biophys 526(2): 194-205.
23. Lejeune FJ, Lienard D, Matter M, Ruegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6: 6.
24. Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14(20): 6515-6524.
25. Massa PE, Paniccia A, Monegal A, de Marco A, Rescigno M (2013) Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. Blood; doi:10.1182/blood-2012-12-474098.
26. Mortara L, Balza E, Sassi F, Castellani P, Carnemolla B, De Lerma Barbaro A, Fossati S, Tosi G, Accolla RS, Borsi L (2007) Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. Eur J Immunol 37(12): 3381-3392.
27. Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, Oliva P,Micotti E, ValbusaG, Schwager K, Kaspar M, Trachsel E, KosmehlH, BaniMR, NeriD, Giavazzi R (2012) Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res 72(7): 1814-1824.
28. Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61(2): 711-716. (Pubitemid 32128637)
29. Olieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS (1997) Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 4(1): 64-69. (Pubitemid 127727873)
30. Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, Alonso C, Hofbauer GF, Boyle RW, Neri D (2011) A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer 104(7): 1106-1115.
31. Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, Ventura E, Gonzalez-Iglesias R, Lovato V, Giovannoni L, Tasciotti A, Neri D, Santinami M, Menssen HD, De Cian F (2012) Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol 107(2): 173-179.
32. Pasche N, Neri D (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17(11-12): 583-590.
33. Pasche N, Woytschak J, Wulhfard S, Villa A, Frey K, Neri D (2011) Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol 154(1): 84-92.
34. Pawelek JM, Low KB, Bermudes D (1997) Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57(20): 4537-4544. (Pubitemid 27441058)
35. Pisters PW (2007) Treatment of localized soft-tissue sarcoma: lessons learned. Oncology 21(6): 731-732, 735.
36. Riedel RF (2012) Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer 118(6): 1474-1485.
37. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A (2004) Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 64(19): 7150-7155. (Pubitemid 39331030)
38. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9(2): 571-579. (Pubitemid 36182586)
39. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Durkop H, Menssen HD (2009) Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113(10): 2265-2274.
40. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33(12): 1718-1722.
41. Schwager K, Villa A, Rosli C, Neri D, Rosli-Khabas M, Moser G (2011) A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol 3: 25.
42. Scoggins CR, Pisters PW (2008) Diagnosis and management of soft tissue sarcomas. Adv Surg 42: 219-228.
43. Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, González-Iglesias R, Giovannoni L, Tasciotti A, Neri D, Menssen HD, de Braud F (2013) Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol 139(3): 447-455.
44. Starnes CO (1992) Coley's toxins in perspective. Nature 357(6373): 11-12.
45. Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, Dinkelborg LM, Leemans CR, Neri D, van Dongen GA (2009) (124) I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 36(8): 1235-1244.
46. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122(11): 2405-2413. (Pubitemid 351590471)